Aidi S, Daneshpazhooh M, Eslami M, et al. - Researchers performed this observational cross‐sectional study to evaluate the arrhythmogenic effects of rituximab (RTX) in pemphigus patients using electrocardiogram (ECG) Holter monitoring. The sample consisted of 80 consecutive patients [median age of the patients was 42 years] with pemphigus who were eligible for RTX infusion. The heart rhythm of patients was monitored before, during and after RTX infusion and ECG parameters were compared before and after the infusion. Findings suggested that RTX has possible arrhythmogenic side effects, namely increased mean and maximum HR, QTc interval, premature atrial contraction and premature ventricular contraction count. However, these results are minor and do not prohibit the infusion of RTX to eligible patients.